|
|
Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry
Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry
Release Date: June 2, 2023
Expiration Date: June 2, 2024
Estimated Time to Complete: 1.25 hour
VIEW ACTIVITY
Clinical Gap and Educational Need
Antiretroviral therapy should be initiated for all persons with HIV who are pregnant regardless of CD4 count according to current guidelines. There is often minimal data available to make recommendations, however, for use in pregnancy. One key consideration is... |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|